1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

immune cell activation

" in MedChemExpress (MCE) Product Catalog:

168

Inhibitors & Agonists

11

Screening Libraries

1

Fluorescent Dye

16

Biochemical Assay Reagents

17

Peptides

29

Inhibitory Antibodies

24

Natural
Products

16

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-102011
    BMS-1166
    4 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
    BMS-1166
  • HY-156574

    DGK Cancer
    DGKζ-IN-4 is a DGK-zeta inhibitor. DGKζ-IN-4 can be used as an active component of pharmaceutical compositions. DGKζ-IN-4 is used to treat cancers associated with immune cell activation or cancers resistant to anti-PD-1 antibody/anti-PD-11 antibody treatment .
    DGKζ-IN-4
  • HY-145239

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 + T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model .
    PD-1/PD-L1-IN-13
  • HY-159114

    Biochemical Assay Reagents Inflammation/Immunology
    Whole Glucan Particles is a Dectin-1a agonist. Whole Glucan Particles activates the innate immune system to improve the function of macrophages, monocytes and other immune cells .
    Whole Glucan Particles
  • HY-155971

    Autophagy Inflammation/Immunology Cancer
    VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .
    VISTA-IN-2
  • HY-147295

    BTH 1677; Imprime PGG

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Odetiglucan is a novel β-glucan that is a potent immunostimulant and a Dectin-1 (CLEC7A) agonist. Odetiglucan activates innate immune effector cells and triggers a coordinated anti-cancer immune response .
    Odetiglucan
  • HY-169017

    Toll-like Receptor (TLR) Cancer
    MTT5 is a toll-like receptor 7 (TLR7) agonist. MTT5 can couple with Deruxtecan (HY-13631E) and exert anti-tumor activity in HER2 positive solid tumors through tumor cell killing and immune activation .
    MTT5
  • HY-P10509

    CMV Infection
    IE1 peptide refers to an antigenic peptide encoded by the immediate early (IE) gene of mouse cytomegalovirus (mCMV). IE1 peptide is one of the key antigenic peptides expressed during mCMV infection, plays a role in transcriptional activation in the life cycle of mCMV, and is one of the earliest genes expressed in the viral replication cycle. IE1 peptide is an important target for CD8+ T cell response and can be used to study the host immune response to mCMV infection .
    IE1 peptide
  • HY-NP134

    Toll-like Receptor (TLR) Cancer
    Flagellin from S. typhimurium is a potent TLR5 agonist. Flagellin activates immune cells and inhibits melanoma cells activity .
    Flagellin from S. typhimurium
  • HY-151506

    Liposome Cancer
    Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .
    Phospholipid PL1
  • HY-N15169

    IFNAR CD74 NO Synthase Arginase Cancer
    BG-136 is an innate immune stimulant isolated from Durvillaea Antarctica that can simultaneously stimulate the activation of both innate and adaptive immune cells in the tumor microenvironment (TME), exerting a broad-spectrum antitumor effect .
    BG-136
  • HY-148029

    TAK-676

    STING Cancer
    Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .
    Dazostinag disodium
  • HY-147236

    Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7/8 agonist 7 (compound 10) is a TLR7/8 agonist. TLR7/8 agonist 7 activates a variety of immune cells and it can be used to synthesize immune stimulating antibody conjugate (ISAC) molecules. TLR7/8 agonist 7 can be used for the research of immunity .
    TLR7/8 agonist 7
  • HY-160197G

    NOD-like Receptor (NLR) Infection Inflammation/Immunology
    Aluminum phosphate adjuvant GMP is a Aluminum phosphate adjuvant produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Aluminum phosphate adjuvant is a safe and effective adjuvant that activates immune system and immune system-related pathways in monocytes .
    Aluminum phosphate adjuvant (GMP)
  • HY-165084

    Soy PS sodium

    Biochemical Assay Reagents Inflammation/Immunology
    L-a-Phosphatidylserine sodium is an antigen targeting phosphatidylserine (PS) and can induce the production of polyclonal antibodies. L-a-Phosphatidylserine can trigger complement-dependent immune damage by binding to PS on the cell membrane surface. After L-a-Phosphatidylserine is recognized by antibodies, it activates the complement system, causing liposome membrane damage and content release, and then participates in the regulation of immune response and cell apoptosis signaling. L-a-Phosphatidylserine can be used in immunological research, such as antibody specificity analysis and complement activation mechanism research .
    L-a-Phosphatidylserine sodium
  • HY-P990046

    Incagn-02385

    LAG-3 Inflammation/Immunology
    Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
    Tuparstobart
  • HY-P991077

    ALT-803; N-803; Anktiva

    Interleukin Related Inflammation/Immunology Cancer
    Nogapendekin alfa inbakicept is a IL-15 superagonist that enhances anti-tumor immune responses by activating NK cells and T cells, and is being studied for the treatment of non-muscle-invasive bladder cancer (NMIBC) .
    Nogapendekin alfa inbakicept
  • HY-N9753

    Others
    Tsukubamycin B is discovered from Streptomyces tsukubaensis and exhibits immunosuppressive activity by inhibiting T-cell activation. Tsukubamycin B can be used for immune rejection reaction research .
    Tsukubamycin B
  • HY-157793

    Toll-like Receptor (TLR) NF-κB MAPKAPK2 (MK2) Inflammation/Immunology Cancer
    SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4 + T and CD8 + T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases .
    SMU-L11
  • HY-160719

    Peptide-Drug Conjugates (PDCs) Inflammation/Immunology
    NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a murine model of primary biliary cholangitis (PBC). NHS-activated 2-octynoic acid-BSA works in conjunction with Complete Freund's Adjuvant (HY-153808) to stimulate the body's immune system, causing the immune system to recognize it as a foreign antigen and trigger an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, resulting in bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for research of primary biliary cholangitis .
    NHS-activated 2-octynoic acid-BSA
  • HY-156677

    METTL3 Cancer
    STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .
    STC-15
  • HY-N3796

    Echinuline

    NF-κB Inflammation/Immunology
    Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to NF-κB activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent .
    Echinulin
  • HY-119339
    SX-682
    5+ Cited Publications

    CXCR Inflammation/Immunology Endocrinology Cancer
    SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity .
    SX-682
  • HY-143869

    MAP4K Cancer
    HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) .
    HPK1-IN-28
  • HY-143870

    MAP4K Cancer
    HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) .
    HPK1-IN-29
  • HY-160406

    STING IFNAR Cancer
    SNX281 is a systemically active non-CDN STING agonist that binds to the STING protein. SNX281 promotes signal transduction of the cGAS-STING pathway, and increases cellular responses to tumor cells. SNX281 activates STING and leads to the production of type I IFNs and proinflammarory cytokines, ultimately stimulating the infilatration of immune cells into the tumor microenvironment. SNX281 enhances anti-tumor immunity, potentially overcoming resistance to checkpoint inhibitors in some cancer. SNX281 can be used in the research for anti-tumor immunity .
    SNX281
  • HY-P991126

    TNF Receptor Inflammation/Immunology Cancer
    Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
    Ciltistotug
  • HY-169225

    PDIC-NS free base

    STING Apoptosis Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    PDIC-NN (PDIC-NS free base) is a STING activator with anticancer activity. PDIC-NN promotes the content and biostability of endogenous cyclic dinucleotides (CDNs). PDIC-NN triggers ROS burst and causes serious damage to mitochondria. PDIC-NN induces cell apoptosis and inhibits DNA replication. PDIC-NN activates cGAS-STING signaling pathway, enhances the immunogenicity of tumor cells and activates a robust innate immune response .
    PDIC-NN
  • HY-155801

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    CRX 527 is a ligand of TLR4 and also serves as an adjuvant for peptide-based cancer vaccines, showing potential to enhance anti-tumor immune responses. CRX 527 can also induce HSC differentiation, increase the proportion and quantity of LSK cells, and promote their differentiation into macrophages, activating immune defense and protecting intestinal epithelium from radiation damage .
    CRX 527
  • HY-P10371

    txCD47

    Reactive Oxygen Species (ROS) Thrombopoietin Receptor Inflammation/Immunology Cancer
    PKHB1 is a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS production, intracellular Ca 2+ accumulation, as well calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation through immunogenic cell death induction in breast cancer cells .
    PKHB1
  • HY-P99514

    AGEN1884

    CTLA-4 Cancer
    Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
    Zalifrelimab
  • HY-148511A

    CMP-001 sodium

    Toll-like Receptor (TLR) Cancer
    Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.
    Vidutolimod sodium
  • HY-169225A

    PDIC-NS

    STING Apoptosis Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    PDIC-NN dimethanesulfonate (PDIC-NS) is a STING activator with anticancer activity. PDIC-NN dimethanesulfonate promotes the content and biostability of endogenous cyclic dinucleotides (CDNs). PDIC-NN dimethanesulfonate triggers ROS burst and causes serious damage to mitochondria. PDIC-NN dimethanesulfonate induces cell apoptosis and inhibits DNA replication. PDIC-NN dimethanesulfonate activates cGAS-STING signaling pathway, enhances the immunogenicity of tumor cells and activates a robust innate immune response .
    PDIC-NN dimethanesulfonate
  • HY-168078

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-50 (Compound LG-12) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-50 increases the secretion of IFN-γ to promote CD8 + T cell activation, and activates the antitumor immunity of T cells .
    PD-1/PD-L1-IN-50
  • HY-P991338

    Orexin Receptor (OX Receptor) Cancer
    MEDI-6469 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .
    MEDI-6469
  • HY-P99653

    VAY-736

    TNF Receptor Cancer
    Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) .
    Ianalumab
  • HY-126346

    GPR84 Inflammation/Immunology
    DL-175 (compound 13) is a selective GPR84 agonist with biased agonistic activity. DL-175 can selectively activate functional responses in immune cells and induce enhanced chemotaxis and phagocytosis of human bone marrow cells. DL-175 is a potential chemical probe .
    DL-175
  • HY-N0454
    DL-Arginine
    4 Publications Verification

    Endogenous Metabolite Cardiovascular Disease
    DL-Arginine is the racemic compound of L-Arginine (HY-N0455) and D-Arginine (HY-W016781). Arginine is an essential amino acid that requires additional supplementation in traumatic or diseased conditions. Arginine is involved in T cell activation, proliferation, and differentiation, and affects the function of immune cells .
    DL-Arginine
  • HY-N6727

    Aspergillin

    Apoptosis PKA NF-κB Bacterial Fungal Antibiotic Infection Inflammation/Immunology Cancer
    Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .
    Gliotoxin
  • HY-155487

    ROR Neurological Disease Inflammation/Immunology
    JTE-151 is a RORγ inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research .
    JTE-151
  • HY-162874

    STING Inflammation/Immunology Cancer
    diABZI-V/C-DBCO (Compound 3) is a potent STING agonist. diABZI-V/C-DBCO can release diABZI-amine upon activation by cathepsin B to activate STING, leading to the production of interferons and other immune-stimulatory molecules, thereby enhancing the immune system's response to tumors. The EC50 values for diABZI-V/C-DBCO and diABZI-amine in activating STING in THP1-Dual cells are 1.47 and 0.144 nM, respectively, and in primary mouse splenocytes, the EC50 values are 7.7 and 0.17 μM, respectively. diABZI-V/C-DBCO can be used in cancer immunotherapy research .
    diABZI-V/C-DBCO
  • HY-148511

    CMP-001

    Toll-like Receptor (TLR) Cancer
    Vidutolimod (CMP-001) is a CpG-A oligodeoxynucleotide. Vidutolimod is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.
    Vidutolimod
  • HY-P991125

    TNF Receptor Inflammation/Immunology Cancer
    Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
    Cenzestotug
  • HY-D1056H
    Lipopolysaccharides, from S. marcescens
    1 Publications Verification

    LPS, from Serratia marcescens

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. marcescens (Serratia marcescens) are lipopolysaccharide endotoxins and TLR-4 activators derived from Serratia marcescens, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. marcescens exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from S. marcescens induce NF-κB activation in mouse cells via Toll-like receptor (TLR4)/MD-2. The lipopolysaccharides of S. marcescens can induce apoptosis in host immune cells, thereby suppressing the host's innate immunity .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from S. marcescens
  • HY-P99166

    PD-1/PD-L1 CTLA-4 Inflammation/Immunology Cancer
    Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
    Vudalimab
  • HY-W040055

    D-(+)-Neopterin; D-erythro-Neopterin

    NF-κB PPAR ERK Raf Src Cardiovascular Disease Inflammation/Immunology
    Neopterin is an immune system activator metabolized by GTP and can be produced by activated macrophages. Neopterin has the potential to resist vascular inflammation and atherosclerosis. Neopterin inhibits the phosphorylation of NF-κB and promotes the expression of PPAR-γ, thereby suppressing the inflammatory response of vascular endothelial cells, reducing the formation of macrophage foam cells, and regulating the migration and proliferation of vascular smooth muscle cells. Neopterin can be used in research fields such as cardiovascular diseases (such as atherosclerosis), inflammation-related diseases and tumor immunomonitoring .
    Neopterin
  • HY-P10869

    Natriuretic Peptide Receptor (NPR) Inflammation/Immunology Cancer
    dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
    dCNP
  • HY-113512

    Influenza Virus Inflammation/Immunology
    17-HDHA is a DHA-derived specialized proresolving mediator (SPM). 17-HDHA enhances the antibody-mediated immune response against influenza virus. 17-HDHA enhances the differentiation of B cells toward the CD27 + CD38 + antibody-secreting cell phenotype, thereby strongly increasing IgM and IgG production by activated B cells .
    17-HDHA
  • HY-P99057

    CDX-1127

    TNF Receptor Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
    Varlilumab
  • HY-159886

    TNF Receptor Inflammation/Immunology
    MG-C-30 is an orally active agonist for CD27 with an EC50 of 0.84 μM. MG-C-30 activates NK cells and T cell co-stimulatory signals, and enhances immune response. MG-C-30 exhibits antitumor efficacy in mouse EG7-OVA model .
    MG-C-30

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: